期刊
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
卷 160, 期 -, 页码 56-70出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.yjmcc.2021.05.006
关键词
m6A RNA modifications; development; cardiovascular disease; mRNA; microRNA; long non-coding RNA
资金
- British Heart Foundation [RG/15/5/31446, CH/15/1/31199]
- Diabetes UK [16/0005564, 18/0005874]
- Luxemburg National Research Fund [C14/BM/8225223, COVID-19/2020-1/14719577/miRCOVID, C17/BM/11613033]
- Luxemburg Ministry of Higher Education and Research
- Luxemburg Heart Foundation - Daniel Wagner of Luxembourg
- British Heart Foundation [RG/15/5/31446, CH/15/1/31199] Funding Source: researchfish
This review highlights the important role of m6A RNA methylation and its components in the cardiovascular system, emphasizing the need for further studies to better understand the mechanisms of action and potential therapeutic implications of this modification in cardiovascular disease.
N6-methyladenosine (m6A) is the most abundant and well-studied internal modification of messenger RNAs among the various RNA modifications in eukaryotic cells. Moreover, it is increasingly recognized to regulate non-coding RNAs. The dynamic and reversible nature of m6A is ensured by the precise and coordinated activity of specific proteins able to insert (write), bind (read) or remove (erase) the m6A modification from coding and non-coding RNA molecules. Mounting evidence suggests a pivotal role for m6A in prenatal and postnatal development and cardiovascular pathophysiology. In the present review we summarise and discuss the major functions played by m6A RNA methylation and its components particularly referring to the cardiovascular system. We present the methods used to study m6A and the most abundantly methylated RNA molecules. Finally, we highlight the possible involvement of the m6A mark in cardiovascular disease as well as the need for further studies to better describe the mechanisms of action and the potential therapeutic role of this RNA modification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据